Erowid References Database
Blackburn JR, Szumlinski KK.
“Ibogaine effects on sweet preference and amphetamine induced locomotion: implications for drug addiction”.
Behav Brain Res. 1997 Dec 03;89(1-2):99-106.
The neural basis of ibogaine's effects on drug-related behaviours is unclear. One possibility is that ibogaine interferes with the shared capacity of many addictive agents to stimulate brain dopamine activity, but reports of ibogaine effects on dopamine activity have been inconsistent. Our study suggests such inconsistencies may result from variations in prior drug exposure. If ibogaine blocks dopamine activity, then it should, like dopamine blockers, decrease preference for natural rewards such as sweet solutions. However, 40 mg/kg ibogaine i.p. did not decrease preference for a glucose + saccharin solution when it was administered to male Long Evans rats 24 h prior to test in Experiment 1. Nor did ibogaine attenuate conditioned preference for a neutral flavour previously paired with sweet taste in Experiment 2. In Experiment 3, effects of 40 mg/kg ibogaine on amphetamine-induced locomotion were investigated in drug-naive and drug-experienced (four prior doses of 1.5 mg/kg amphetamine) rats. Locomotion was significantly lower in those ibogaine-treated rats that had previously been exposed to amphetamine than in those that had not. Thus, ibogaine may serve to decrease induced levels of dopamine activity in drug-experienced animals or humans from elevated, sensitized levels back to baseline levels. This could lead to a reduction of sensitized levels of drug craving in addiction.
[ Cite HTML